JP2019521705A - 細胞内増殖のための改変糖タンパク質hを有するヘルペスウイルス - Google Patents
細胞内増殖のための改変糖タンパク質hを有するヘルペスウイルス Download PDFInfo
- Publication number
- JP2019521705A JP2019521705A JP2019517157A JP2019517157A JP2019521705A JP 2019521705 A JP2019521705 A JP 2019521705A JP 2019517157 A JP2019517157 A JP 2019517157A JP 2019517157 A JP2019517157 A JP 2019517157A JP 2019521705 A JP2019521705 A JP 2019521705A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- herpesvirus
- peptide
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
- C12N2710/16652—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
61 PPRGFLAPPD ELNLTTASLP LLRWYEERFC FVLVTTAEFP RDPGQLLYIP KTYLLGRPPN
121 ASLPAPTTVE PTAQPPPSVA PLKGLLYNPV ASVLLRSRAW VTFSAVPDPE ALTFPRGDNV
181 ATASHPSGPR DTPPPRPPVG ARRHPTTELD ITHLHNASTT WLATRGLLRS PGRYVYFSPS
241 ASTWPVGIWT TGELVLGCDA ALVRARYGRE FMGLVISMHD SPPVEVMVVP AGQTLDRVGD
301 PADENPPGAL PGPPGGPRYR VFVLGSLTRA DNGSALDALR RVGGYPEEGT NYAQFLSRAY
361 AEFFSGDAGA EQGPRPPLFW RLTGLLATSG FAFVNAAHAN GAVCLSDLLG FLAHSRALAG
421 LAARGAAGCA ADSVFFNVSV LDPTARLQLE ARLQHLVAEI LEREQSLALH ALGYQLAFVL
481 DSPSAYDAVA PSAAHLIDAL YAEFLGGRVL TTPVVHRALF YASAVLRQPF LAGVPSAVQR
541 ERARRSLLIA SALCTSDVAA ATNADLRTAL ARADHQKTLF WLPDHFSPCA ASLRFDLDES
601 VFILDALAQA TRSETPVEVL AQQTHGLAST LTRWAHYNAL IRAFVPEASH RCGGQSANVE
661 PRILVPITHN ASYVVTHSPL PRGIGYKLTG VDVRRPLFLT YLTATCEGST RDIESKRLVR
721 TQNQRDLGLV GAVFMRYTPA GEVMSVLLVD TDNTQQQIAA GPTEGAPSVF SSDVPSTALL
781 LFPNGTVIHL LAFDTQPVAA IAPGFLAASA LGVVMITAAL AGILKVLRTS VPFFWRRE*
配列ID番号1
配列ID番号1:gH野生型、HSV‐1由来の前駆体(ヒトヘルペスウイルス1 F株、ジェンバンク(GenBank)アセッション番号:GU734771.1;位置43741〜46498によりコードされたgH)のアミノ酸配列。
配列ID番号2:キメラgH‐GCN4のヌクレオチド配列。
配列ID番号3:構築物R‐VG213によりコードされた、アミノ酸23及び24の間にGCN4ペプチドを挿入したgH前駆体(配列ID番号1)のアミノ酸配列。GCN4ペプチドにはGly‐Serリンカーが隣接している。
配列ID番号4:ヒトコドン使用(human codon usage)に最適化され、シグナル配列及びHAタグを形成する96ヌクレオチドに先行される、GCN4ペプチドに対するscFvのヌクレオチド配列。
配列ID番号5:シグナル配列及びHAタグを構成する33AAに先行される、GCN4ペプチドに対するscFv(ジェンバンク1P4B)のアミノ酸配列。GCN4ペプチドに対するscFvの配列はアミノ酸33から始まる。
配列ID番号6:scFv‐GCN4ネクチン1キメラのヌクレオチド配列。
配列ID番号7:scFv‐GCN4ネクチン1キメラのアミノ酸配列。
配列ID番号8:プライマーgH5_galK_r
配列ID番号9:プライマーgH6_galK_f
配列ID番号10:プライマーgalK_129_f
配列ID番号11:プライマーgalK_417_r
配列ID番号12:GCN4ペプチドカセット‐上流及び下流GSリンカーにより挟まれたGCN4ペプチドのヌクレオチド配列。
配列ID番号13:GCN4ペプチド‐上流及び下流GSリンカーにより挟まれたGCN4ペプチドのアミノ酸配列。
配列ID番号14:サッカロマイセスセレビシエ(Saccharomyces cerevisiae)GCN4mRNA(http://www.ncbi.nlm.nih.gov/nuccore/15811626/)に由来するGCN4エピトープ。
配列ID番号15:オリゴヌクレオチドGCN4gH_23_42_fB
配列ID番号16:オリゴヌクレオチドGCN4gH_23_24_rB
配列ID番号17:プライマーgH_ext_rパリーノ(pallino)
配列ID番号18:プライマーgH_2176_2200_f
配列ID番号19:ジェンバンクアセッション番号AJ585687.1(GCN4酵母転写因子をコードする遺伝子)
配列ID番号20:GCN4酵母転写因子UniProtKB‐P03069(GCN4_YEAST)のアミノ酸配列
Abstract # P-28, 9th International conference on Oncolytic virus Therapeutics, Boston 2015
Arndt K. and Fin G.R., PNAS 1986, 83, 8516-8520
Backovic M. et al., PNAS, 2012, 107, 22635-22640
Chowdary T.K. et al., Nat Struct Mol Biol, 2010, 17, 882-888
Douglas J.T. et al., Nat Biotechnol, 1999, 17, 470-475
Florence G. et al., Virology: A Laboratory Manual, 1992, ISBN-13: 978-0121447304
Gatta V. et al., PLOS Pathogens, 2015, DOI: 10.1371/journal.ppat.1004907
Hope I.A. and Struhl K., EMBO J, 1987, 6, 2781-2784
Karlin S. and Altschul S.F., PNAS, 1990, 87, 2264-2268
Karlin S.and Altschul S.F., PNAS, 1993, 90, 5873-5877
Matsuura H. et al., PNAS, 2010, 107, 22641-22646
Menotti L, et al., J Virol, 2008, 82, 10153-10161; doi: 10.1128/JVI.01133-08. Epub 2008 Aug 6.
Nakamura T. et al., Nat Biotechnol, 2005, 23, 209-214. Epub 2005 Jan 30
Needleman S.B. and Wunsch C. D., J Mol Biol, 1970, 48, 443-453
Pearson W.R. and Lipman D. J., PNAS, 1988, 85, 2444-2448
Peterson R.B. and Goyal S.M., Comp Immunol Microbiol Infect Dis. 1988, 11, 93-98
Sandri-Goldin R.M. et al., Alpha Herpesviruses: Molecular and Cellular Biology, Caister Academic Press, 2006
Smith T.F. and Waterman M.S., Add APL Math, 1981, 2, 482-489
Zahnd C. et al.., J Biol Chem 2004; 279, 18870-18877
Claims (19)
- ヘルペスウイルスのエンベロープ内に存在する糖タンパク質H(gH)に融合又は挿入された、5〜274アミノ酸の長さを有するペプチドを備える組み換えヘルペスウイルス。
- 前記ペプチドが、5〜200アミノ酸、好ましくは11〜29、31〜39、41〜49又は51〜200アミノ酸、より好ましくは12〜20アミノ酸の長さを有する請求項1に記載のヘルペスウイルス。
- 前記ペプチドが、GCN4酵母転写因子の一部、好ましくは配列ID番号13により備えられるGCN4酵母転写因子の一部を備え、最も好ましくは前記ペプチドが配列ID番号13により特定されるペプチドである請求項1又は2に記載のヘルペスウイルス。
- 前記ペプチドが、配列ID番号1に係る前記gHのアミノ酸19〜23のいずれかから始まりアミノ酸48〜88のいずれかで終わり若しくはアミノ酸116から始まりアミノ酸136で終わるN末端領域内又は相同gHの対応領域内において挿入される請求項1〜3のいずれかに記載のヘルペスウイルス。
- 前記ペプチドが、gHのH1AドメインのN末端側に挿入される請求項1〜4のいずれかに記載のヘルペスウイルス。
- N末端領域の1つ以上のgHアミノ酸が欠失している請求項1〜5のいずれかに記載のヘルペスウイルス。
- 前記ヘルペスウイルスが、標的分子を発現させ又は結合させている細胞に前記ペプチドを介して結合する能力、好ましくは当該細胞膜と融合する能力、より好ましくは前記細胞に侵入する能力、最も好ましくは前記細胞内で増殖する能力を有する請求項1〜6のいずれかに記載のヘルペスウイルス。
- 前記標的分子が、配列ID番号5により備えられるscFv、最も好ましくは配列ID番号7の配列により特定される分子である請求項7に記載のヘルペスウイルス。
- 前記ヘルペスウイルスが、前記ヘルペスウイルスを疾患細胞に再標的化するように改変されたgD及び/又は前記ヘルペスウイルスを疾患細胞に再標的化するように改変されたgBを備える請求項1〜8のいずれかに記載のヘルペスウイルス。
- 前記ヘルペスウイルスが、細胞、好ましくは疾患細胞に対する宿主免疫応答を刺激する1つ以上の分子をコードする請求項1〜9のいずれかに記載のヘルペスウイルス。
- 請求項1〜10のいずれかに記載のヘルペスウイルスと薬学的に許容可能な担体とを備える医薬組成物であって、随意的に、細胞、好ましくは疾患細胞に対する宿主免疫応答を刺激する1つ以上の分子を追加的に備える医薬組成物。
- 腫瘍、感染、変性疾患又は老化関連疾患の治療における使用のために、随意的に、細胞、好ましくは疾患細胞に対する宿主免疫応答を刺激する1つ以上の分子と組み合わされる請求項1〜10のいずれかに記載のヘルペスウイルス。
- 前記ペプチドを融合又は挿入した請求項1〜8のいずれかに記載のgHをコードする核酸を備える核酸分子。
- 請求項13に記載の核酸分子を備えるベクター。
- 前記ペプチドを融合又は挿入した請求項1〜8のいずれかに記載のgHを備えるポリペプチド。
- 請求項1〜10のいずれかに記載のヘルペスウイルス、請求項13に記載の核酸分子、請求項14に記載のベクター、又は請求項15に記載のポリペプチドを備える細胞。
- 前記細胞が、ヘルペスウイルスの増殖に適した培養細胞、より好ましくはヘルペスウイルスの増殖のために認められた細胞株、更に好ましくはVero、293、293T、HEp‐2、HeLa、BHK、又はRS細胞、最も好ましくはVero細胞である請求項16に記載の細胞。
- 細胞又は請求項16若しくは17に記載の細胞であって、前記細胞が、請求項1〜10のいずれかに記載の組み換えヘルペスウイルスにより備えられる前記ペプチド、好ましくはGCN4酵母転写因子の一部、最も好ましくは前記細胞の表面上でアクセス可能な、配列ID番号13により備えられるGCN4酵母転写因子の一部、に結合可能な人工分子を備え、好ましくは、前記人工分子が、抗体、より好ましくは抗体誘導体、更に好ましくはscFv、更に好ましくはGCN4酵母転写因子の一部に結合可能なscFv、更に好ましくは配列ID番号13により備えられるGCN4酵母転写因子の一部に結合可能なscFv、更に好ましくは配列ID番号5により備えられるscFv、最も好ましくは配列ID番号7の配列により特定される分子である、細胞。
- 請求項1〜10のいずれかに記載のヘルペスウイルスを用いて細胞において組み換えヘルペスウイルスを産生するためのインビトロな方法であって、前記細胞が、請求項1〜9のいずれかに記載の組み換えヘルペスウイルスにより備えられる前記ペプチド、好ましくはGCN4酵母転写因子の一部、最も好ましくは前記細胞の表面上でアクセス可能な、配列ID番号13により備えられるGCN4酵母転写因子の一部、に結合可能な人工分子を備え、好ましくは、前記人工分子が、抗体、より好ましくは抗体誘導体、更に好ましくはscFv、更に好ましくはGCN4酵母転写因子の一部に結合可能なscFv、更に好ましくは配列ID番号13により備えられるGCN4酵母転写因子の一部に結合可能なscFv、更に好ましくは配列ID番号5により備えられるscFv、最も好ましくは配列ID番号7の配列により特定される分子である、インビトロな方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16173831 | 2016-06-09 | ||
EP16173831.5 | 2016-06-09 | ||
PCT/EP2017/063949 WO2017211945A1 (en) | 2016-06-09 | 2017-06-08 | Herpesvirus with modified glycoprotein h for propagation in a cell |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019521705A true JP2019521705A (ja) | 2019-08-08 |
JP7072807B2 JP7072807B2 (ja) | 2022-05-23 |
Family
ID=56132785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019517157A Active JP7072807B2 (ja) | 2016-06-09 | 2017-06-08 | 細胞内増殖のための改変糖タンパク質hを有するヘルペスウイルス |
Country Status (8)
Country | Link |
---|---|
US (1) | US20190300862A1 (ja) |
EP (1) | EP3469072B1 (ja) |
JP (1) | JP7072807B2 (ja) |
KR (1) | KR20190043520A (ja) |
CN (1) | CN109642218A (ja) |
AU (1) | AU2017276727B2 (ja) |
CA (1) | CA3025124A1 (ja) |
WO (1) | WO2017211945A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
MX2019013312A (es) | 2017-05-08 | 2020-08-17 | Flagship Pioneering Innovations V Inc | Composiciones para facilitar la fusion de membranas y usos de estas. |
AU2019269593A1 (en) * | 2018-05-15 | 2020-11-26 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
AU2021287122A1 (en) * | 2020-06-12 | 2022-11-24 | Gencellmed Inc. | Recombinant Herpes Simplex Virus comprising glycoprotein GH that has been modified for retargeting, and use thereof |
CN112501137B (zh) * | 2020-11-11 | 2023-10-20 | 深圳先进技术研究院 | 一种神经环路标记系统 |
WO2022216915A1 (en) | 2021-04-08 | 2022-10-13 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2729011A1 (en) * | 2007-07-19 | 2009-01-22 | Novavax, Inc. | Varicella zoster virus-virus like particles (vlps) and antigens |
GB0714578D0 (en) * | 2007-07-26 | 2007-09-05 | Crusade Lab Ltd | Viruses |
-
2017
- 2017-06-08 JP JP2019517157A patent/JP7072807B2/ja active Active
- 2017-06-08 AU AU2017276727A patent/AU2017276727B2/en active Active
- 2017-06-08 KR KR1020197000478A patent/KR20190043520A/ko active IP Right Grant
- 2017-06-08 US US16/307,708 patent/US20190300862A1/en active Pending
- 2017-06-08 EP EP17730107.4A patent/EP3469072B1/en active Active
- 2017-06-08 CN CN201780048885.4A patent/CN109642218A/zh active Pending
- 2017-06-08 WO PCT/EP2017/063949 patent/WO2017211945A1/en unknown
- 2017-06-08 CA CA3025124A patent/CA3025124A1/en active Pending
Non-Patent Citations (5)
Title |
---|
AVITABILE E: "COMPLEXES BETWEEN HERPES SIMPLEX VIRUS GLYCOPROTEINS GD, GB, AND GH DETECTED IN CELLS BY 以下備考", JOURNAL OF VIROLOGY, vol. VOL:81, NR:20, JPN5019005772, August 2007 (2007-08-01), US, pages 11532 - 11537, ISSN: 0004545985 * |
CAIRNS T M: "STRUCTURE-FUNCTION ANALYSIS OF HERPES SIMPLEX VIRUS TYPE 1 GD AND GH-GL: CLUES FROM GDGH CHIMERAS", JOURNAL OF VIROLOGY, vol. VOL:77, NR:12, JPN5019005775, 15 June 2003 (2003-06-15), pages 6731 - 6742, ISSN: 0004545989 * |
JOURNAL OF VIROLOGY, vol. 80, no. 11, JPN6021025375, 2006, pages 5531 - 5539, ISSN: 0004545988 * |
LORENTZEN E U: "REPLICATION-COMPETENT HERPES SIMPLEX VIRUS TYPE 1 MUTANT EXPRESSING AN AUTOFLUORESCENT 以下備考", INTERVIROLOGY, vol. VOL:44, NR:4, JPN5019005773, 1 January 2001 (2001-01-01), CH, pages 232 - 242, ISSN: 0004545986 * |
VALENTINA GATTA: "THE ENGINEERING OF A NOVEL LIGAND IN GH CONFERS TO HSV AN EXPANDED TROPISM INDEPENDENT OF 以下備考", PLOS PATHOGENS, vol. VOL:11, NR:5, JPN5019005774, 21 May 2015 (2015-05-21), pages 1004907 - 1, ISSN: 0004545987 * |
Also Published As
Publication number | Publication date |
---|---|
CN109642218A (zh) | 2019-04-16 |
EP3469072A1 (en) | 2019-04-17 |
AU2017276727A1 (en) | 2018-12-06 |
CA3025124A1 (en) | 2017-12-14 |
KR20190043520A (ko) | 2019-04-26 |
JP7072807B2 (ja) | 2022-05-23 |
AU2017276727B2 (en) | 2023-10-05 |
US20190300862A1 (en) | 2019-10-03 |
EP3469072B1 (en) | 2021-08-04 |
WO2017211945A1 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7072807B2 (ja) | 細胞内増殖のための改変糖タンパク質hを有するヘルペスウイルス | |
CN107406834B (zh) | 具有糖蛋白h融合体的重靶向疱疹病毒 | |
US11998581B2 (en) | Herpesvirus with modified glycoprotein B | |
EP3469071B1 (en) | Herpesvirus with modified glycoprotein d |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220405 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220425 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7072807 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |